FDA gives nod to AtriCure's LAA exclusion system

Kaitlyn Dmyterko | | Health Imaging | Screening
The FDA has given the green light to AtriCure’s AtriClip Gillinov-Cosgrove left atrial appendage (LAA) exclusion system for use in conjunction with other open-heart cardiac procedures.

According to the West Chester, Ohio-based company, the AtriClip system is equipped with a clip device that excludes the LAA during an intervention to prevent the formation of blood pools in the LAA that have the potential to clot, particularly during atrial fibrillation.

The company said that marketing of the product will begin next month and the full release will begin in the third quarter of this year.

Kaitlyn Dmyterko

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.